Loading…
Jyong Biotech Ltd. is projected to rise to $2.69 by 2027, a +22% move from its current price of $2.21. MENS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.11 | $2.21 | $2.31 | -0.02% |
| Jul 14 | $2.08 | $2.21 | $2.35 | -0.04% |
| Jul 15 | $2.05 | $2.21 | $2.38 | -0.05% |
| Jul 16 | $2.02 | $2.21 | $2.41 | -0.07% |
| Jul 17 | $2.00 | $2.21 | $2.44 | -0.09% |
| Jul 18 | $1.98 | $2.21 | $2.46 | -0.11% |
| Jul 19 | $1.96 | $2.21 | $2.48 | -0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.96 | $2.21 | $2.48 | -0.12% |
| Week 2 | $1.87 | $2.20 | $2.60 | -0.25% |
| Week 3 | $1.80 | $2.20 | $2.70 | -0.37% |
| Week 4 | $1.74 | $2.20 | $2.78 | -0.50% |
| Week 5 | $1.69 | $2.20 | $2.85 | -0.62% |
| Week 6 | $1.65 | $2.19 | $2.92 | -0.74% |
| Week 7 | $1.61 | $2.19 | $2.99 | -0.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Jyong Biotech Ltd. (MENS) is a healthcare biotechnology company that develops and commercializes plant-derived drugs for urinary system diseases in the United States, the European Union, and Asia. Its programs include Botreso for benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
The company was founded in 2002 and is headquartered in New Taipei City, Taiwan. It is categorized in Healthcare.
Jyong Biotech Ltd. trades as MENS and is currently priced at $2.20 per share. Its market capitalization is $167.26M and it holds the rank of 3746. The current price sits in a landscape where the 30-day forecast implies a potential path higher, with a long-run bull outlook reflected in the year-by-year forecast that grows from a 2026 average price of $2.20 toward substantially higher levels by 2050 (average $22.00, max $50.61).
A major floor 41.9% below — a decisive break under it would weaken the trend.
The nearest floor, 29.4% below — buyers have tended to step in here.
The nearest ceiling, 4.1% above — a clean break opens room to run.
A major ceiling 26.2% above — clearing it would confirm fresh momentum.
Key MENS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MENS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.21 | Sell | $2.20 | Buy |
| MA 10 | $2.15 | Buy | $2.13 | Buy |
| MA 20 | $1.90 | Buy | $2.04 | Buy |
| MA 50 | $2.01 | Buy | $2.16 | Buy |
| MA 100 | $2.12 | Buy | $4.20 | Sell |
| MA 200 | $14.42 | Sell | $9.16 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.98 | Neutral |
| Stoch RSI (14) | 84.01 | Sell |
| CCI (20) | 82.65 | Neutral |
| Williams %R (14) | -12.68 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 34.76 | Buy |
| Bollinger %B (20,2) | 0.79 | Neutral |
| Stochastic %K (14) | 87.32 | Sell |
| TRIX (15) | 0.11 | Buy |
| Awesome (5,34) | 0.24 | Buy |
| Ultimate (7,14,28) | 65.12 | Neutral |
| Momentum (10) | 0.31 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 2.26 | Sell |
| ADX (14) | 21.03 | Buy |
| ATR (14) | 0.08 | Info |
The technical picture is BULLISH. RSI14 is 60, indicating constructive momentum near the upper end of the neutral range. The stock’s near-term moving averages show SMA50 at $2.02 and SMA200 at $16.64. Immediate support sits at $1.56 and resistance at $2.25, with a 30-day price range of $1.59 to $3.04.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.46 | $2.21 | $3.14 | 0% | Neutral | |
| $1.93 | $2.69 | $4.06 | +22% | Bullish | |
| $2.35 | $3.49 | $5.63 | +58% | Bullish | |
| $2.53 | $3.98 | $6.74 | +80% | Bullish | |
| $2.59 | $4.28 | $7.56 | +94% | Bullish | |
| $2.64 | $4.57 | $8.36 | +107% | Bullish | |
| $2.27 | $4.13 | $7.80 | +87% | Bullish | |
| $2.37 | $4.49 | $8.72 | +103% | Bullish | |
| $2.94 | $5.81 | $11.59 | +163% | Bullish | |
| $3.29 | $6.79 | $13.86 | +207% | Bullish | |
| $3.50 | $7.77 | $17.48 | +252% | Bullish | |
| $8.69 | $19.31 | $44.40 | +774% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.46 | $2.21 | $2.64 | +0.00% |
| August 2026 | $1.70 | $2.06 | $2.61 | -6.64% |
| September 2026 | $1.76 | $2.17 | $2.82 | +5.39% |
| October 2026 | $1.83 | $2.29 | $3.02 | +5.29% |
| November 2026 | $1.79 | $2.25 | $3.02 | -1.51% |
| December 2026 | $1.81 | $2.31 | $3.14 | +2.57% |
Click any year to see its month-by-month MENS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MENS is projected to trade between $1.46 and $3.14, averaging $2.21 — a potential gain of 0% from today's $2.21. Price action looks broadly range-bound.
Jyong Biotech Ltd.'s 2027 outlook centres on $2.69, within a $1.93 to $4.06 range. That is up +22% on the projected 2026 average. That marks a +22% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, MENS could reach as high as $5.63, with a base case around $3.49 and support toward $2.35 — roughly +58% from $2.21. Momentum favours further upside here.
Expect MENS to range from $2.53 to $6.74 through 2029. The $3.98 average target implies a +80% move from current prices. That is up +14% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The MENS price prediction for 2030 points to an average of $4.28 (low $2.59, high $7.56) — a potential gain of +94% on today's $2.21. Momentum favours further upside here.
In 2031, MENS is projected to trade between $2.64 and $8.36, averaging $4.57 — a potential gain of +107% from today's $2.21. That is up +7% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Jyong Biotech Ltd.'s 2032 outlook centres on $4.13, within a $2.27 to $7.80 range. That is -10% versus the projected 2031 average. That marks a +87% change versus current levels. Momentum favours further upside here.
By 2033, MENS could reach as high as $8.72, with a base case around $4.49 and support toward $2.37 — roughly +103% from $2.21. Buyers look set to stay in control over this stretch.
Expect MENS to range from $2.94 to $11.59 through 2034. The $5.81 average target implies a +163% move from current prices. That is up +30% on the projected 2033 average. Momentum favours further upside here.
The MENS price prediction for 2035 points to an average of $6.79 (low $3.29, high $13.86) — a potential gain of +207% on today's $2.21. Buyers look set to stay in control over this stretch.
In 2040, MENS is projected to trade between $3.50 and $17.48, averaging $7.77 — a potential gain of +252% from today's $2.21. That is up +14% on the projected 2035 average. Momentum favours further upside here.
Jyong Biotech Ltd.'s 2050 outlook centres on $19.31, within a $8.69 to $44.40 range. That is up +148% on the projected 2040 average. That marks a +774% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in MENS today (≈ 452.488688 MENS) could be worth
$8,735.64
+$7,735.64 (+774%) by 2050 · US Dollar
Based on the average projected MENS price of $19.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MENSwould be worth at today's price.
$1,000 invested in MENS on Jul 10, 2025 (≈ 109.769488 MENS) would be worth
$242.59
-$757.41 (-75.7%) today · 0.24× · US Dollar
Based on a MENS entry price of $9.11 vs. today's $2.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.22 | $995.5 | -0.5% |
| 1 month ago | $1.72 | $1,284.88 | +28.5% |
| 3 months ago | $2.49 | $887.55 | -11.2% |
| 6 months ago | $3.56 | $620.79 | -37.9% |
| 1 year ago | $9.11 | $242.59 | -75.7% |
| All time (1.1y) ago | $10.11 | $218.6 | -78.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MENS forecast.
Our base-case forecast reaches $4.40 around 2031.
Implied market cap at $4.40: $326.63M
The multi-year forecast shows a bullish trajectory with an initial neutral stance in 2026 (min $1.46, avg $2.20, max $3.33; ROI 0; sentiment NEUTRAL) and a progressive shift to bullish sentiment in following years. By 2030 the average price is projected at $4.52 with an ROI of 105.7% and a bullish outlook; 2030’s min is $2.57 and max is $8.36. The forecast continues to rise through 2040, with an average of $8.23 and an ROI of 274.2%, and culminates in 2050 with an average of $22.00, a max of $50.61, and an ROI of 900.1%.
The outlook remains BULLISH across the longer horizon (2031: avg $4.71; 2032: avg $4.38; 2033: avg $4.69; 2034: avg $6.28; 2035: avg $7.54). Note that volatility is implied by the wide yearly ranges and a high annualized volatility figure (90%), underscoring that these are estimates, not guarantees. The forecast implies upside potential from current levels but also substantial uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $4.52, with a min of $2.57 and a max of $8.36; ROI is 105.7% and sentiment is BULLISH.
The forecast depicts bullish sentiment beginning in 2027 and rising averages through 2050, with an average price around $22.00 by 2050 and an ROI of 900.1%; note that 2026 is neutral with an average of $2.20 and ROI of 0, so outcomes are not guaranteed.
Yes—the forecast shows a 2050 max of $50.61, indicating the potential to approach that level under the modeled scenario.
From 2026 to 2050, the average price climbs from $2.20 to $22.00, with cumulative bullish sentiment after 2026 and a 2050 ROI of 900.1%. Key milestones include 2030 avg $4.52 and 2040 avg $8.23, highlighting sustained upside potential along with higher volatility.
The asset shows high volatility, with an annualized volatility of 90% and a 30-day price range of $1.59 to $3.04, reflecting substantial potential swings despite the longer-run bullish forecast.
Jyong Biotech Ltd. Community Discussion
0Share your Jyong Biotech Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.